Article

Acute hepatitis B by sexual transmission after interruption of lamivudine-containing antiretroviral regimen.

G Liuzzi, M Zaccarelli, P Sette, S Grisetti, L Alba, A Antinori

AIDS (impact factor: 6.24). 11/2001; 15(15):2062-3. pp.2062-3

Source: PubMed

0 0

0 Bookmarks

17 Views

Source
Available from: Antoinette C van der Kuyl

Article: HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil.

Suzanne Jurriaans, Sanjay U C Sankatsing, Jan M Prins, Hanneke Schuitemaker, Joep Lange, Antoinette C Van Der Kuyl, Marion Cornelissen

AIDS 08/2004; 18(11):1607-8. · 6.24 Impact Factor

Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Acute hepatitis B by sexual transmission after interruption of lamivudine-containing antiretroviral regimen.

Article: HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil.

View other sources

Hide other sources

View other sources

Hide other sources

Similar Publications

SWIFT: Prospective 48 Week Study to Evaluate Efficacy and Safety of Switching to Emtricitibine/Tenofovir from Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen.

Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.

Virologic failure with a raltegravir-containing antiretroviral regimen and concomitant calcium administration.

Andrea Antinori

Acute hepatitis B by sexual transmission after interruption of lamivudine-containing antiretroviral regimen.

Article: HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil.

View other sources

Hide other sources

View other sources

Hide other sources

Similar Publications

SWIFT: Prospective 48 Week Study to Evaluate Efficacy and Safety of Switching to Emtricitibine/Tenofovir from Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen.

Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.

Virologic failure with a raltegravir-containing antiretroviral regimen and concomitant calcium administration.

Andrea Antinori

Log in